In microeconomic theory, the partial equilibrium supply and demand economic model originally developed by Alfred Marshall attempts to describe, explain, and predict changes in the price and quantity of goods sold in competitive markets. The model is only a first approximation for describing an imperfectly competitive market. It formalizes the theories used by some economists before Marshall and is one of the most fundamental models of some modern economic schools, widely used as a basic building block in a wide range of more detailed economic models and theories. The theory of supply and demand is important for some economic schools' understanding of a market economy in that it is an explanation of the mechanism by which many resource allocation decisions are made. However, unlike general equilibrium models, supply schedules in this partial equilibrium model are fixed by unexplained forces.

Supply

---

Supply is the quantity that producers are willing to sell at a given price. For example, the potato grower may be willing to sell 1 million lb of potatoes if the price is $0.75 per lb and substantially more if the market price is $0.90 per lb. The main determinants of supply will be the market price of the good and the cost of producing it. In fact, supply curves are constructed from the firm's long-run cost schedule. Supply curves are traditionally represented as upward-sloping because of the law of diminishing marginal returns. This need not be the case, however, as described below.

Special cases of a supply curve

---

More on [ Supply and demand ]

Clinical Chemistry current issue

[Editorials] Cerebrospinal Fluid Biomarkers in the Evaluation of Alzheimer Disease
Verbeek, M. M., Olde Rikkert, M. G.M. Mon, 29 Sep 2008 00:00:00 -0000

[Editorials] Rapid and Effective Screening for Lysosomal Storage Disease: How Close Are We?
Millington, D. S. Mon, 29 Sep 2008 00:00:00 -0000

[Editorials] Requesting and Interpreting Urine Albumin Measurements in the Primary Health Care Setting
McQueen, M. J., Don-Wauchope, A. C. Mon, 29 Sep 2008 00:00:00 -0000

[Editorials] Multiple Thiopurine S-Methyltransferase Variation Detection: A Step toward Personalized Medicine
Tsui, N. B. Y. Mon, 29 Sep 2008 00:00:00 -0000

[Mini-Review] Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers
Emami, N., Diamandis, E. P. Mon, 29 Sep 2008 00:00:00 -0000
Background: The human kallikrein-related peptidase (KLK) family consists of 15 highly conserved serine proteases, which are encoded by the largest uninterrupted cluster of protease genes in the human genome. To date, several members of the family have been reported as potential cancer biomarkers. Although primarily known for their biomarker value in prostate, ovarian, and breast cancers, more recent data suggest analogous roles of KLKs in several other cancers, including gastrointestinal, head and neck, lung, and brain malignancies. Among the proposed KLK cancer biomarkers, prostate-specific antigen (also known as KLK3) is the most widely recognized member in urologic oncology. Content: Despite substantial progress in the understanding of the biomarker utility of individual KLKs, the current challenge lies in devising biomarker panels to increase the accuracy of prognosis, prediction of therapy, and diagnosis. To date, multiparametric KLK panels have been proposed for prostate, ovarian, and lung cancers. In addition to their biomarker utility, emerging evidence has revealed a number of critical functional roles for KLKs in the pathogenesis of cancer and their potential use as therapeutic targets. Summary: KLKs have biomarker utility in many cancer types but individually lack sufficient specificity or sensitivity to be used in clinical practice; however, groups of KLKs and other candidate biomarkers may offer improved performance.
[Mini-Review] High-Abundance Polypeptides of the Human Plasma Proteome Comprising the Top 4 Logs of Polypeptide Abundance
Hortin, G. L., Sviridov, D., Anderson, N. L. Mon, 29 Sep 2008 00:00:00 -0000
Background: Plasma contains thousands of proteins, but a small number of these proteins comprise the majority of protein molecules and mass. Content: We surveyed proteomic studies to identify candidates for high-abundance polypeptide chains. We searched the literature for information on the plasma concentrations of the most abundant components in healthy adults and for the molecular mass of the mature polypeptide chains in plasma. Because proteomic studies usually dissociate proteins into polypeptide chains or detect short peptide segments of proteins, we summarized data on individual peptide chains for proteins containing multiple subunits or polypeptides. We collected data on about 150 of the most abundant polypeptides in plasma. The abundant polypeptides span approximately the top 4 logs of concentration in plasma, from 650 to 0.06 µmol/L on a molar basis or from about 50 000 to 1 mg/L mass abundance. Conclusions: Data on the concentrations of the high-abundance peptide chains in plasma assist in understanding the composition of plasma and potential approaches for clinical laboratory or proteomic analysis of plasma proteins. Development of more extensive databases regarding the plasma concentrations of proteins in health and diseases would promote diagnostic and proteomic advances.

Subscribe to Chemistry RSS feed